We continue to monitor the medical literature for developments related to gadolinium retention in connection with our investigation of cases of Gadolinium Deposition Disease (GDD) in patients who received injections of gadolinium based contrast agents for their MRI, MRA, or CT scan procedure. Presented below is a collection of medical articles … [Read more...]
May 2018 Gadolinium Deposition Disease Update Issued By Health Canada
In May 2018 Health Canada announced the results of its second safety review of Magnevist, MultiHance, Omniscan, and Optimark, as well as other gadolinium contrast injections for MRIs, CT scans, and other radiology procedures. In May 2018 Health Canada issued this document, “Summary Safety Review – Gadolinium based contrast agents – Assessing the … [Read more...]
Gadolinium Retention Higher For Linear Agents Than Macrocyclic Agents
Gadolinium Based Contrast Agents (GBCAs) are substances that are injected into patients during a Magnetic Resonance Imaging (MRI) or Magnetic Resonance Angiography (MRA) in order to produce clearer radiology images. However, as explained below, unfortunately some patients have experienced gadolinium side effects after these contrast agents were … [Read more...]
MRI Contrast Agents: Gadolinium Retention Warnings Added To Drug Label
The gadolinium contrast agents safety warnings announced by the FDA in December 2017 started to be seen on new drug labels approved in the spring of 2018. It is important to understand that symptoms of gadolinium-related medical conditions can first appear anywhere from just a few hours until several weeks after the MRI or MRA procedure when a … [Read more...]
Gadolinium Deposition Disease Explained: How It Is Diagnosed, And More
A person who received an injection of a gadolinium-based contrast agent (GBCA) may develop some medical conditions following their MRI or MRA procedure which could be symptoms of gadolinium deposition disease. These various gadolinium-related symptoms include: Persistent headache; “Brain fog”; Skin that appears spongy or rubbery, … [Read more...]
Gadolinium-Based Contrast Agents: Timeline of FDA Regulatory Actions
In my last article on Gadolinium based contrast agents (GBCAs), I discussed some of the side effects of these injections, which are administered to patients during a Magnetic Resonance Imaging (MRI) or Magnetic Resonance Angiography (MRA). While GBCAs have started to draw attention in the pharmaceutical products liability legal realm, they have … [Read more...]
Gadolinium Deposition Disease can Result from use of Contrast Agents During MRI & MRA Procedures
What are Gadolinium-Based Contrast Agents (GBCAs)? GBCAs are substances that are injected into patients during Magnetic Resonance Imaging (MRI) or Magnetic Resonance Angiography (MRA) in order to produce clearer radiology images. Here is a list of GBCAs that are currently approved by the FDA: Ablavar Dotarem Eovist Gadavist … [Read more...]